The FDA IND clearance for oral elraglusib is a meaningful clinical milestone that de-risks the oral formulation pathway, but the going concern disclosure (cash only through July 2026) creates existential near-term risk. The strong Phase 2 mPDAC data supports the drug's potential, but the company will likely need to raise capital via dilutive financing within weeks/months. Monitor for equity offering announcements and upcoming RAS inhibitor synergy data expected mid-2026.
Price Chart
Executive Summary
Actuate Therapeutics announced FDA clearance of an Investigational New Drug (IND) application to conduct a Phase 1/2 study of its oral elraglusib tablet formulation in advanced solid tumors, with initiation planned for 2H 2026. The company also reported positive Phase 2 data in metastatic pancreatic cancer (mPDAC) showing elraglusib + GnP doubled 1-year overall survival vs GnP alone (44.4% vs 22.3%, p=0.0004) and improved median OS by 40% (HR 0.62, p=0.02). However, the filing explicitly states the company's financial condition raises substantial doubt about its ability to continue as a going concern, requiring additional capital to fund operations beyond July 2026.
Key Facts
- FDA cleared IND for Phase 1/2 study of oral elraglusib tablet in advanced solid tumors (melanoma, NSCLC, colorectal, pancreatic cancers), initiation planned for 2H 2026
- Phase 2 RCT in 1L mPDAC (n=233) met primary endpoint: elraglusib + GnP doubled 1-year OS vs GnP alone (44.4% vs 22.3%, p=0.0004)
- Elraglusib + GnP improved median OS by 40% vs GnP alone (HR 0.62, p=0.02)
- 2.5x increase in 1-year OS in patients with liver metastases (p=0.0003)
- Company's financial condition raises substantial doubt about ability to continue as a going concern; requires additional capital to fund operations beyond July 2026
- Nonclinical studies show >95% bioavailability for oral tablet formulation
- IP provides exclusivity to 2038 before PTE in all major markets
- Potential for pediatric review voucher worth $150-200 million
- Martin Huber, MD, former CEO of Mersana Therapeutics, joined Board of Directors
Financial Impact
No revenue or earnings reported; company is pre-revenue clinical-stage biotech. Cash runway only through July 2026 per going concern disclosure.
Risk Factors
- Going concern risk: company requires additional capital to fund operations beyond July 2026
- Dilution risk from likely near-term equity financing given $78M market cap and limited cash runway
- Clinical risk: oral formulation Phase 1/2 data may not replicate IV formulation efficacy
- Regulatory risk: no assurance of FDA/EMA approval for any indication
- Single-product dependency on elraglusib
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-003684 |
| Document: actuate_8k.htm | 0001683168-26-003684 |
| Document: actuate_ex9901.htm | 0001683168-26-003684 |
| Document: 0001683168-26-003684-index-headers.html | 0001683168-26-003684 |
| Document: 0001683168-26-003684-index.html | 0001683168-26-003684 |
| Document: 0001683168-26-003684.txt | 0001683168-26-003684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $0.3548 | awaiting T+5 | — | $0.4052 (−14.21%) |
Oct 27, 2026 today | EFFECT | $0.5200 | awaiting T+5 | — | $0.4052 (+22.08%) |
Oct 19, 2026 8d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.4052 (+32.35%) |
Oct 14, 2026 13d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.4052 (+6.68%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.4052 (+44.03%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.4052 (+58.22%) |
Jun 9, 2026 20w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.4052 (−79.84%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.4052 (−85.98%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4052 (−86.45%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4052 (−86.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers